Equillium, Inc.
Moat Score — Equillium, Inc.
Total Moat Score
4 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Owns patent portfolios covering AhR modulator chemistry (via the Ariagen acquisition) and IL-15/IL-21 peptide antagonists (via the Bioniz acquisition), giving it real but early-stage, unproven intellectual property rather than an approved, protected franchise. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a 14-person preclinical company with no manufacturing or commercial scale, Equillium has no cost advantage versus peers; it relies on third-party CMOs like any similarly-sized biotech. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | No approved products and no revenue means there is currently no pricing power to assess; any future pricing power is purely speculative and years away. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Biotech drug development has no network effect dynamics; value is driven by clinical data and IP, not by user or participant scale. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product and no patients or prescribers currently using any Equillium therapy, there are no switching costs to speak of today. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Celiac disease and ulcerative colitis are large but not so large that only one or two specialized players can serve them efficiently; some scale advantage could emerge post-approval, but it is premature at the preclinical stage. |